OvAge: an innovative, user-friendly digital methodology that quantifies ovarian reserve by integrating clinical, biochemical and 3D-sonographic data to help decision-making in all phases of woman life

Información del proyecto

Ovage

Identificador del acuerdo de subvención: 781853

DOI

10.3030/781853

Proyecto cerrado

Fecha de la firma de la CE 31 Julio 2017

Fecha de inicio 1 Agosto 2017

Fecha de finalización 31 Enero 2018

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

OVAGE SRL
Italy

Objetivo

OvAge s.r.l. is the owner of a pioneering patented medical device-software able in quantifying women ovarian reserve (both in term of fertility potential and distance to menopause) by integrating clinical, biochemical and 3D-ultrasonographic data.
For the first time in this field of medicine, this instrument, also called OvAge®, gives as a result explicitly the ovarian age of a woman, a ready-to-use information that is going to revolutionize the relationship of women with themselves and with the Specialists in the field of Gynaecology.
OvAge s.r.l. objective is to diffuse its innovative research product all over the world, with the purpose of helping both women (healthy or affected by infertility, benign or malignant pathologies) and physicians (general and specialists) in the management of many frequent conditions affecting the reproductive life of a woman.
In this way, OvAge® aims to contribute the sustainability of health care systems, by reducing both costs related to late diagnosis of infertility and those related to useless surgeries in women affected by benign pathologies for which menopause is the best and cheaper therapy. Moreover, OvAge® will solve women needs for life planning by predicting reproductive potential and for safely solving common pathologies by predicting distance to menopause.
To reach these goals, a feasibility study is needed. It will produce a market study for each European member state,proposals on best practice to enhance customer loyalty, a risk assessment of the plan and a potential licensing in order to launch OvAge® software medical device in the EU market initially through a web site. Later, OvAge s.r.l. aim to commercialize its product in the rest of the world (phase 2) as a medical hardware device.
The most relevant market segment for OvAge® is the population of women residents in all EU countries, although our challenges and markets are global, since infertility and female pathologies are the same in all parts of the world.

Ámbito científico (EuroSciVoc)

• ciencias médicas y de la salud › ciencias de la salud › salud pública y medio ambiental
• ciencias médicas y de la salud › medicina clínica › cirugía
• ciencias sociales › sociología › demografía › fecundidad
• ciencias médicas y de la salud › medicina básica › patología
• ciencias médicas y de la salud › medicina clínica › ginecología

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being PROGRAMA PRINCIPAL
  
• H2020-EU.3.1.4. - Active ageing and self-management of health
  
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
  
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
  
• H2020-EU.3.1.6. - Health care provision and integrated care
  

Tema(s)

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
  

Régimen de financiación

SME-1 - SME instrument phase 1

Convocatoria de propuestas

H2020-SMEInst-2016-2017

Coordinador

OVAGE SRL

• Aportación neta de la UEn: € 50 000,00
• Dirección: VIA PERTINI 1 ; 88056 TIRIOLO ; Italia
• Pyme Sí:
  Región
  Sud › Calabria › Catanzaro
• Región: Sud › Calabria › Catanzaro
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00